Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynectics Regulatory News (SNX)

Share Price Information for Synectics (SNX)

Share Price is delayed by 15 minutes
Get Live Data
200.00    0.00 (0.00%)
Bid:
195.00
Ask:
205.00
Spread: 10.00 (5.128%)
Market Cap: £34.01m
SNX Live PriceLast checked at - London Stock Exchange

Intraday Synectics Share Chart

Director/PDMR Shareholding

11 May 2018 15:38

RNS Number : 8690N
Synectics PLC
11 May 2018
 

 

11 May 2018

 

 

 

Synectics plc

(the 'Company')

Exercise of Options under Share Plan and subsequent Sale of Shares

PDMR shareholdings

 

Synectics (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, announces that on 9 May 2018 the following share options, which vested under the performance criteria of its Performance Share Plan ('PSP'), were exercised and either held or sold by Executive Directors and other Persons Discharging Managerial Responsibility ('PDMRs').

 

 

Number of shares

Name

Position

Status

PSP options exercised

Of which, subsequently held in own name

Of which, subsequently sold

Paul Webb*

Chief Executive, Synectics plc

Executive Director and PDMR

50,000

26,322

23,678

Mike Stilwell

Finance Director, Synectics plc

Executive Director and PDMR

25,000

-

25,000

David Aindow

Business Strategy Director, Synectic Systems Group Limited

PDMR

25,000

-

25,000

Darren Alder

Divisional Director, Oil & Gas, Synectic Systems Group Limited

PDMR

7,500

-

7,500

Stacey Anderson

Managing Director, SSS Management Services

PDMR

7,500

-

7,500

Jeff Fail

Organisational Development Director, Synectics plc

PDMR

30,000

-

30,000

 

*Paul Webb, Chief Executive, sold sufficient shares to cover the immediate tax liability on exercise of the options. The balance of 26,322 shares were transferred into his own name.

 

Following these transactions, their total interests in Synectics shares are now as follows:

 

Name

Position

Ordinary shares held

Interest in shares in share schemes

Resultanttotalinterest

% ofissuedshare capital

Paul Webb

Chief Executive, Synectics plc

36,322

251,325

287,647

1.62%

Mike Stilwell

Finance Director, Synectics plc

6,910

26,273

33,183

0.19%

David Aindow

Business Strategy Director, Synectic Systems Group Limited

-

13,000

13,000

0.07%

Darren Alder

Divisional Director, Oil & Gas, Synectic Systems Group Limited

-

15,000

15,000

0.08%

Stacey Anderson

Managing Director, SSS Management Services

-

16,000

16,000

0.09%

Jeff Fail

Organisational Development Director, Synectics plc

-

14,000

14,000

0.08%

 

 

 

Full details of the PSP are set out in the Company's Annual Report for the year ended 30 November 2017.

 

Commenting, Paul Webb, Chief Executive, said:

 

"I am very pleased that the Company's performance has led to the vesting in full of the share awards issued in March 2015.

 

"I have chosen to retain the maximum number of shares from my award after selling sufficient to cover the immediate tax liability. Other award holders have made their own individual choices."

 

 

For further information, please contact:

Synectics plc

Tel: +44 (0) 1527 850 080

Jan Mitson, Deputy Company Secretary

www.synecticsplc.com

Stockdale Securities

Tel: +44 (0) 20 7601 6100

Tom Griffiths/Henry Willcocks

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHEALSFFDKPEFF
Date   Source Headline
7th Apr 20217:00 amRNSSynectics secures major City of London project
31st Mar 20217:00 amRNSHolding(s) in Company
23rd Mar 20217:00 amRNSPosting of Accounts and Notice of AGM
17th Mar 20217:00 amRNSDirector’s/PCA’s Interest in Shares
4th Mar 20217:00 amRNSPDMR’s Interest in Shares
2nd Mar 20217:00 amRNSFinal Results
17th Feb 20217:00 amRNSFurther contract wins in Irish bus market
10th Feb 20217:00 amRNSLetter of Intent and Notification of Results Date
7th Jan 20217:00 amRNSSynectics’ S-Bahn project goes live
15th Dec 20207:00 amRNSTrading Update
1st Dec 20207:00 amRNSSynectics appoints Dr Kerstin Wendt
26th Nov 20207:00 amRNSDirector/PDMR Shareholding
19th Nov 20207:36 amRNSDirector/PDMR Shareholding
18th Nov 202011:53 amRNSDirector/PDMR Shareholding
17th Nov 20207:00 amRNSContract Win
2nd Oct 202011:02 amRNSDirector/PDMR dealings
29th Sep 20207:00 amRNSTrading Update
12th Aug 20207:00 amRNSDirector/PDMR Shareholding
10th Aug 20207:00 amRNSDirectors' / PDMRs' Interests in Shares
30th Jul 20202:03 pmRNSDirector/PDMR Shareholding
28th Jul 20207:00 amRNSDirector/PDMR Shareholding
28th Jul 20207:00 amRNSContract Wins for 'next generation' Irish Buses
27th Jul 20204:40 pmRNSSecond Price Monitoring Extn
27th Jul 20204:35 pmRNSPrice Monitoring Extension
27th Jul 20207:00 amRNSHolding(s) in Company
23rd Jul 20208:22 amRNSHolding(s) in Company
14th Jul 20207:00 amRNSInterim Results
25th Jun 20209:12 amRNSHolding(s) in Company
16th Jun 20207:00 amRNSMajor Contract Win and Notice of Interim Results
22nd May 20207:00 amRNSContract Wins with Long Term Customers
23rd Apr 202011:49 amRNSResult of AGM
23rd Apr 20207:00 amRNSBusiness Update
6th Apr 202012:24 pmRNSRevised Arrangements for Annual General Meeting
2nd Apr 20209:11 amRNSDirector/PDMR Shareholding
23rd Mar 20202:28 pmRNSBusiness Update: COVID-19
23rd Mar 20201:48 pmRNSAvailability of Report and Accounts and AGM
11th Mar 20204:23 pmRNSDirector/PDMR Shareholding
11th Mar 202012:11 pmRNSHolding(s) in Company
6th Mar 20201:59 pmRNSDirector/PDMR Shareholding
25th Feb 20207:00 amRNSSettlement of Legal Claim
25th Feb 20207:00 amRNSFinal Results
11th Feb 20204:12 pmRNSHolding(s) in Company
7th Feb 20202:33 pmRNSHolding(s) in Company
7th Feb 202010:43 amRNSReplacement - Holding(s) in Company
7th Feb 20207:00 amRNSNotification of Final Results
6th Feb 20204:58 pmRNSHolding(s) in Company
30th Jan 202012:17 pmRNSReplacement - Holding(s) in Company
28th Jan 20208:58 amRNSHolding(s) in Company
23rd Jan 20209:55 amRNSDirectorate Changes
13th Dec 201912:00 pmRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.